Healthcare
Cellectis S.A.(CMVLF)
Live Price
Offline$3.47
+0.00% today
1Y Change
+177.60%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $270.00M
- Revenue Growth
- +82.9%
- EPS Growth
- -70.7%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cellectis S.A. (CMVLF) is a Healthcare stock with a market cap of $270.00M and listed on OTC. The stock last traded around $3.47 and up 177.6% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +82.9%, EPS growth of -70.7%, a dividend yield of 0.0%. What stands out right now is revenue +82.9%, EPS -70.7%, free cash flow -330.3% with operating margin -47.6% and ROIC -17.5%. Valuation is more restrained than many high-expectation growth names at price/sales 3.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CMVLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+82.9% vs +7.6% peer median
Operating Margin
Below sector median
-47.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 18, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +82.9% and EPS is at -70.7%, with operating margin around -47.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 18, 2026 | โ | +0.0% | +0.0% | โ |
2026 Mar 19, 2026 | -28.6% | +0.0% | +0.0% | -30.0% |
2025 Nov 7, 2025 | +102.5% | +0.0% | +0.0% | -10.7% |
Benchmark Edge
CMVLF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CMVLF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CMVLF Max Drawdown
-38.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CMVLF and SPY.
Company Overview
Cellectis S.A.
OTC
Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of next-generation immunotherapies for cancer. With over 25 years of innovation, Cellectis leverages its proprietary TALENยฎ gene-editing technology to engineer chimeric antigen receptor (CAR) T-cells, creating "off-the-shelf" allogeneic therapies designed to be widely accessible to cancer patients. Unlike traditional personalized cell therapies, these products use donor-derived cells, aiming to reduce manufacturing times and improve scalability. Cellectisโ product pipeline targets a range of hematologic malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma. The company operates significant research and manufacturing infrastructure, enabling end-to-end control over the cell and gene therapy value chain. Strategic collaborations with global biotechnology and pharmaceutical partners help advance its programs and expand the reach of its platform technology. Headquartered in Paris with additional presence in New York, Cellectis holds a robust intellectual property portfolio and is recognized as a pioneer in the field of genome editing and cellular immunotherapy.
- Leadership
- Dr. Andre Choulika Ph.D.
- Employees
- 216
- Street Address
- 8, rue de la Croix Jarry
- Mailing
- Paris, 75013
- Region
- Paris, France
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.7
- Price/Book
- 4.9
Growth
- Revenue
- +82.9%
- EPS
- -70.7%
- Free Cash Flow
- -330.3%
Profitability
- Gross Margin
- 83.6%
- Operating Margin
- -47.6%
- Net Margin
- -92.9%
- ROE
- -69.6%
- ROIC
- -17.5%
Balance Sheet
- Debt/Equity
- 1.58
- Current Ratio
- 1.62
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.